Drugs / rhIL-11
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00038922 | — | ulcerative colitis | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02314273 | Sep 2011 → Apr 2014 | pancytopenia | Shanghai Children's Medical Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03823079 Comparator | Feb → Sep 2019 | colorectal carcinoma, thrombocytopenia | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT01663441 Comparator | Mar 2015 → Aug 2017 | thrombocytopenia | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIL-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00038922 ↗ |
| Known as | Recombinant Human Interleukin-11 | “A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079 ↗ |
| Modality | Protein / enzyme biologic | “Orally Administered Recombinant Human Interleukin Eleven (rhIL-11)” NCT00038922 ↗ |
| Route | Oral | “orally delivered rhIL-11” NCT00038922 ↗ |